Is nitric oxide a key target in the pathogenesis of brain lesions during the development of Alzheimer's disease?

Ali Aliyev, Dilara Seyidova, Nizami Rzayev, Mark E. Obrenovich, Bruce Lamb, Shu G. Chen, Mark A. Smith, George Perry, Jack C. De La Torre, Gjumrakch Aliev

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Nitric oxide (NO) is a short-life key bioregulatory active molecule in the cardiovascular, immune and nervous systems. NO is synthesized by converting L-arginine to L-citrulline by enzymes called NO synthase (NOS). The growing body of evidence strongly supports the theory that this molecule appears to be one of the key targets for the disruption of normal brain homeostasis, which causes the development of brain lesions and pathology such as in Alzheimer's disease (AD) or other related dementia. The vascular content of NO activity appears especially to be a main contributor to this pathology before the over-expression of other NOS isoforms activity in a different brain cellular compartment. We speculate that pharmacological intervention using NO donors and/or NO suppressors will be able to delay or minimize the development of brain pathology and further progression of mental retardation.

Original languageEnglish (US)
Pages (from-to)547-553
Number of pages7
JournalNeurological Research
Volume26
Issue number5
DOIs
StatePublished - Jul 2004
Externally publishedYes

Fingerprint

Alzheimer Disease
Nitric Oxide
Brain
Pathology
Nitric Oxide Synthase
Citrulline
Nitric Oxide Donors
Cardiovascular System
Intellectual Disability
Nervous System
Blood Vessels
Arginine
Dementia
Immune System
Protein Isoforms
Homeostasis
Pharmacology
Enzymes

Keywords

  • Brain hypoperfusion
  • Dementia
  • Nitric oxide, Alzheimer's disease
  • Oxidative stress

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)

Cite this

Is nitric oxide a key target in the pathogenesis of brain lesions during the development of Alzheimer's disease? / Aliyev, Ali; Seyidova, Dilara; Rzayev, Nizami; Obrenovich, Mark E.; Lamb, Bruce; Chen, Shu G.; Smith, Mark A.; Perry, George; De La Torre, Jack C.; Aliev, Gjumrakch.

In: Neurological Research, Vol. 26, No. 5, 07.2004, p. 547-553.

Research output: Contribution to journalArticle

Aliyev, A, Seyidova, D, Rzayev, N, Obrenovich, ME, Lamb, B, Chen, SG, Smith, MA, Perry, G, De La Torre, JC & Aliev, G 2004, 'Is nitric oxide a key target in the pathogenesis of brain lesions during the development of Alzheimer's disease?', Neurological Research, vol. 26, no. 5, pp. 547-553. https://doi.org/10.1179/01610425017613
Aliyev, Ali ; Seyidova, Dilara ; Rzayev, Nizami ; Obrenovich, Mark E. ; Lamb, Bruce ; Chen, Shu G. ; Smith, Mark A. ; Perry, George ; De La Torre, Jack C. ; Aliev, Gjumrakch. / Is nitric oxide a key target in the pathogenesis of brain lesions during the development of Alzheimer's disease?. In: Neurological Research. 2004 ; Vol. 26, No. 5. pp. 547-553.
@article{84426c5fb7a9435db9f3240abe13834c,
title = "Is nitric oxide a key target in the pathogenesis of brain lesions during the development of Alzheimer's disease?",
abstract = "Nitric oxide (NO) is a short-life key bioregulatory active molecule in the cardiovascular, immune and nervous systems. NO is synthesized by converting L-arginine to L-citrulline by enzymes called NO synthase (NOS). The growing body of evidence strongly supports the theory that this molecule appears to be one of the key targets for the disruption of normal brain homeostasis, which causes the development of brain lesions and pathology such as in Alzheimer's disease (AD) or other related dementia. The vascular content of NO activity appears especially to be a main contributor to this pathology before the over-expression of other NOS isoforms activity in a different brain cellular compartment. We speculate that pharmacological intervention using NO donors and/or NO suppressors will be able to delay or minimize the development of brain pathology and further progression of mental retardation.",
keywords = "Brain hypoperfusion, Dementia, Nitric oxide, Alzheimer's disease, Oxidative stress",
author = "Ali Aliyev and Dilara Seyidova and Nizami Rzayev and Obrenovich, {Mark E.} and Bruce Lamb and Chen, {Shu G.} and Smith, {Mark A.} and George Perry and {De La Torre}, {Jack C.} and Gjumrakch Aliev",
year = "2004",
month = "7",
doi = "10.1179/01610425017613",
language = "English (US)",
volume = "26",
pages = "547--553",
journal = "Neurological Research",
issn = "0161-6412",
publisher = "Maney Publishing",
number = "5",

}

TY - JOUR

T1 - Is nitric oxide a key target in the pathogenesis of brain lesions during the development of Alzheimer's disease?

AU - Aliyev, Ali

AU - Seyidova, Dilara

AU - Rzayev, Nizami

AU - Obrenovich, Mark E.

AU - Lamb, Bruce

AU - Chen, Shu G.

AU - Smith, Mark A.

AU - Perry, George

AU - De La Torre, Jack C.

AU - Aliev, Gjumrakch

PY - 2004/7

Y1 - 2004/7

N2 - Nitric oxide (NO) is a short-life key bioregulatory active molecule in the cardiovascular, immune and nervous systems. NO is synthesized by converting L-arginine to L-citrulline by enzymes called NO synthase (NOS). The growing body of evidence strongly supports the theory that this molecule appears to be one of the key targets for the disruption of normal brain homeostasis, which causes the development of brain lesions and pathology such as in Alzheimer's disease (AD) or other related dementia. The vascular content of NO activity appears especially to be a main contributor to this pathology before the over-expression of other NOS isoforms activity in a different brain cellular compartment. We speculate that pharmacological intervention using NO donors and/or NO suppressors will be able to delay or minimize the development of brain pathology and further progression of mental retardation.

AB - Nitric oxide (NO) is a short-life key bioregulatory active molecule in the cardiovascular, immune and nervous systems. NO is synthesized by converting L-arginine to L-citrulline by enzymes called NO synthase (NOS). The growing body of evidence strongly supports the theory that this molecule appears to be one of the key targets for the disruption of normal brain homeostasis, which causes the development of brain lesions and pathology such as in Alzheimer's disease (AD) or other related dementia. The vascular content of NO activity appears especially to be a main contributor to this pathology before the over-expression of other NOS isoforms activity in a different brain cellular compartment. We speculate that pharmacological intervention using NO donors and/or NO suppressors will be able to delay or minimize the development of brain pathology and further progression of mental retardation.

KW - Brain hypoperfusion

KW - Dementia

KW - Nitric oxide, Alzheimer's disease

KW - Oxidative stress

UR - http://www.scopus.com/inward/record.url?scp=3042806294&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3042806294&partnerID=8YFLogxK

U2 - 10.1179/01610425017613

DO - 10.1179/01610425017613

M3 - Article

VL - 26

SP - 547

EP - 553

JO - Neurological Research

JF - Neurological Research

SN - 0161-6412

IS - 5

ER -